XASX
ANR
Market cap842kUSD
Jul 09, Last price
0.01AUD
1D
0.00%
1Q
0.00%
Jan 2017
-99.43%
IPO
-98.38%
Name
Anatara Lifesciences Ltd
Chart & Performance
Profile
Anatara Lifesciences Limited engages in the research, development, and commercializing of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease; and 3FDC for the treatment of anxiety, stress, or depression. The company also provides Detach for the treatment of diarrhea disease in piglets; BONIFF, a revised formulation to dry feed for piglets after weaning; and ANR-pf, a proprietary formulation for poultry water. Anatara Lifesciences Limited was incorporated in 2010 and is based in Carlton, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | |
Income | |||||||||
Revenues | |||||||||
Cost of revenue | 2,852 | 3,285 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (2,852) | (3,285) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (626) | (1,215) | |||||||
Tax Rate | |||||||||
NOPAT | (2,226) | (2,070) | |||||||
Net income | (1,451) -28.27% | (2,023) -20.10% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 1,985 | 1,320 | |||||||
BB yield | -31.51% | -45.20% | |||||||
Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 3 | ||||||||
Net debt | (982) | (401) | |||||||
Cash flow | |||||||||
Cash from operating activities | (1,247) | (2,258) | |||||||
CAPEX | (2) | ||||||||
Cash from investing activities | 50 | (2) | |||||||
Cash from financing activities | 1,828 | 1,491 | |||||||
FCF | (2,087) | (2,334) | |||||||
Balance | |||||||||
Cash | 982 | 401 | |||||||
Long term investments | |||||||||
Excess cash | 982 | 401 | |||||||
Stockholders' equity | 1,365 | 925 | |||||||
Invested Capital | 385 | 524 | |||||||
ROIC | |||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 150,017 | 104,303 | |||||||
Price | 0.04 50.00% | 0.03 -49.09% | |||||||
Market cap | 6,301 115.74% | 2,920 -32.11% | |||||||
EV | 5,319 | 2,519 | |||||||
EBITDA | (2,850) | (3,260) | |||||||
EV/EBITDA | |||||||||
Interest | 2 | ||||||||
Interest/NOPBT |